Skip to main content
TipRanks
Go Ultimate75% OFF

Sinco Pharmaceuticals Holdings Ltd. (6833) AI Stock Analysis

0 Followers
HK:6833

Sinco Pharmaceuticals Holdings Ltd.

(HKEX:6833)

Select Model
Rating:54Neutral
Price Target:HKD 0.12â–²(4.27% Upside)
Action:reiterated
Date:11/04/26

The score is primarily constrained by deteriorating profitability, volatile cash flow, and weak technical positioning below all major moving averages. A strengthening balance sheet, low P/E ratio, and modest dividend yield provide meaningful support.

Positive Factors
Improving Balance SheetThe sustained reduction in leverage improves financial resilience and reduces the burden of debt service. Growing equity provides a stronger capital base, giving Sinco more flexibility to withstand operating pressure and support its distribution business over the next several quarters.
Negative Factors
Sharp Revenue ContractionThe reversal from earlier growth to an approximately 18% revenue decline signals pressure on business scale and demand conversion. Persistent contraction could reduce operating leverage, weaken bargaining power, and make it harder for Sinco to rebuild profitability over the medium term.

Sinco Pharmaceuticals Holdings Ltd. (6833) vs. iShares MSCI Hong Kong ETF (EWH)

-50%-40%-30%-20%-10%0%10%20%HK:6833-40.91%EWH+9.54%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 264.28M
Dividend Yield
1.43%
Average Volume (3M)
182.91K
Price to Earnings (P/E)
6.4
Beta (1Y)
-0.20
Revenue Growth
-20.04%
EPS Growth
-25.66%
Country
Hong Kong
Employees
257
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

Sinco Pharmaceuticals Holdings Ltd. Business Overview & Revenue Model

Company Description

Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its prod...

Sinco Pharmaceuticals Holdings Ltd. Financial Statement Overview

Summary

Weakening profitability and volatile cash flow weigh on the score, despite a relatively sound and improving balance sheet. The score reflects the income statement score of 42, balance sheet score of 65, and cash flow score of 45.

Income Statement

42Neutral

Balance Sheet

65Positive

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.92B2.08B2.82B2.54B2.27B2.02B
Gross Profit213.81M222.09M299.94M323.28M305.87M364.95M
EBITDA90.60M99.83M138.44M126.01M112.58M199.25M
Net Income30.39M34.85M42.05M42.35M69.46M135.08M
Balance Sheet
Total Assets2.11B1.85B2.00B1.89B1.42B1.23B
Cash, Cash Equivalents and Short-Term Investments369.41M374.53M308.32M437.92M329.14M326.05M
Total Debt116.76M183.47M350.54M251.40M192.41M340.95M
Total Liabilities1.40B1.15B1.34B1.26B820.52M857.88M
Stockholders Equity710.88M694.36M662.88M628.05M603.81M374.89M
Cash Flow
Free Cash Flow305.00M159.71M-268.05M289.16M22.39M282.19M
Operating Cash Flow313.45M169.49M-232.88M353.70M75.08M305.71M
Investing Cash Flow-29.46M-27.09M-52.87M-63.63M-119.27M-22.73M
Financing Cash Flow-250.63M-197.24M154.59M-189.73M35.04M-97.11M

Sinco Pharmaceuticals Holdings Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.12

Price Trends

50DMA0.14Negative
100DMA0.15Negative
200DMA0.17Negative

Market Momentum

MACD-0.01Positive
RSI35.48Neutral
STOCH39.17Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6833, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.14, and below the 200-day MA of 0.17, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 35.48 is Neutral, neither overbought nor oversold. The STOCH value of 39.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6833.

Sinco Pharmaceuticals Holdings Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:6833 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1099HK:109965NeutralHKD 52.02B6.308.33%4.74%2.78%7.71%
HK:2607HK:260758NeutralHKD 62.90B11.606.64%6.01%9.12%-3.22%
HK:9886HK:988656NeutralHKD 1.06B-15.04-3.87%―8.73%80.38%
HK:6833HK:683354NeutralHKD 237.85M6.434.33%1.43%-20.04%-25.66%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:1110HK:111051NeutralHKD 227.44M16.861.89%8.45%-13.82%112.24%
HK:2289HK:228947NeutralHKD 592.92M10.867.70%6.26%14.25%0.83%

* Healthcare Sector Average

Performance Comparison

-40%-20%0%HK:6833HK:2607HK:1099HK:9886HK:1110HK:2289Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:6833 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:6833Sinco Pharmaceuticals Holdings Ltd.0.12-0.08-40.91%
HK:2607Shanghai Pharmaceuticals Holding Co Class H10.87-0.42-3.73%
HK:1099Sinopharm Group Co Class H16.67-2.78-14.29%
HK:9886Dingdang Health Technology Group Ltd.0.87-0.20-18.69%
HK:1110Kingworld Medicines Group Ltd.0.38-0.14-26.47%
HK:2289Charmacy Pharmaceutical Co., Ltd. Class H5.49-1.14-17.23%

Sinco Pharmaceuticals Holdings Ltd. Corporate Events

Sinco Pharmaceuticals’ Interim Profit Falls as Revenue Declines Despite Margin Improvement

Aug 28, 2026

Sinco Pharmaceuticals reported interim revenue of RMB1.03 billion for the six months ended 30 June 2026, down 13.7% year-on-year, mainly due to weaker sales of pharmaceutical products and a small decline in medical beauty service income. Despite the...

Sinco Pharmaceuticals strengthens board with new independent directors

Aug 28, 2026

Sinco Pharmaceuticals Holdings Ltd. has appointed Mr. Dong Yingjie and Mr. Ye Guowei as independent non-executive directors, effective 28 August 2026, strengthening the company’s board oversight and governance structure. The move is expected to enhan...

Sinco Pharmaceuticals Details Board and Committee Structure

Aug 28, 2026

Sinco Pharmaceuticals Holdings Limited has announced the current composition of its board of directors, detailing the executive, non-executive and independent non-executive directors, including the chairman and lead independent director. The company...

Sinco Pharmaceuticals Sets August Board Meeting to Review Interim Results and Dividend

Aug 18, 2026

Sinco Pharmaceuticals Holdings Limited has scheduled a board meeting for 28 August 2026 to review and approve the interim results of the company and its subsidiaries for the six months ended 30 June 2026. The board will also consider whether to recom...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026